Bavarian Nordic A/S engages in the business of developing, manufacturing, and commercializing cancer immunotherapies and vaccines for infectious diseases. The firm is involved in research and development innovations, production and commercialization of life-saving vaccines based on viral vectors for the delivery of antigens targeting infectious diseases. Bavarian Nordic A/S offers travel health products including cholera, rabies, tick-borne encephalitis and typhoid vaccines, as well as vaccines sold and distributed in selected markets on behalf of third parties. The firm deals with vaccines aimed at improving public health and preparedness. Bavarian Nordic A/S focuses on vaccine solutions that help address the threat of infectious diseases. The firm operates worldwide.
Dr. Paul Chaplin is the President of Bavarian Nordic A/S, joining the firm since 2014.
What is the price performance of Bavarian Nordic A/S stock?
The current price of Bavarian Nordic A/S is $9.65, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Bavarian Nordic A/S?
Bavarian Nordic A/S belongs to Biotechnology industry and the sector is Health Care
What is Bavarian Nordic A/S market cap?
Bavarian Nordic A/S's current market cap is $2.2B
Is Bavarian Nordic A/S a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Bavarian Nordic A/S, including 0 strong buy, 0 buy, 3 hold, 4 sell, and 0 strong sell